(Q44371738)

2 December 2017

Levetiracetam monotherapy for primary generalised epilepsy (English)

1 reference

2 December 2017

1 reference

Jeffrey Cohen

1

1 reference

2 December 2017

1 April 2003

1 reference

Seizure-European Journal of Epilepsy

2 December 2017

1 reference

2 December 2017

12

1 reference

2 December 2017

3

1 reference

2 December 2017

150-153

1 reference

The management of refractory idiopathic epilepsies

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

Efficacy of levetiracetam: a review of three pivotal clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

Pharmacokinetic considerations in prescribing antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

Issues in the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900273-X

7 January 2021

10.1016/S1059-1311(02)00273-X

Identifiers

DOI

1 reference

2 December 2017

1 reference

PubMed ID

12651079